Pharmaceutical Technology
DECEMBER 3, 2024
Many machines are required for pharmaceutical milling processes. Can you reduce that number, streamline operations and improve efficiency?
Bio Pharma Dive
DECEMBER 3, 2024
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 3, 2024
MRI scans of the human brain. (corelens/Canva) Decreases in brain volume are used as an indicator of Alzheimer’s disease, yet the latest class of Alzheimer’s treatments cause the brain to shrink even further. A new study now suggests this might paradoxically be a good thing.
Bio Pharma Dive
DECEMBER 3, 2024
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
DECEMBER 3, 2024
Turkiye’s pharmaceutical industry has grappled with significant economic challenges such as the frequent upward revision of the pharmaceutical Euro exchange rate.
Rethinking Clinical Trials
DECEMBER 3, 2024
In a new report from the NIH Pragmatic Trials Collaboratory, a team of bioethicists explores the ethical obligation to share aggregate results from pragmatic clinical trials with research participants. They conclude with recommendations for how to meet this obligation. The article was published online ahead of print in Clinical Trials. There is growing appreciation of the importance of sharing aggregate results of clinical trials with research participants.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 3, 2024
The Indian healthcare industry is of the view that convergence of AI and wearable technology will stall emergency medical interventions. With the advancement of AI and wearable technology, the healthcare industry is experiencing a seismic shift.
Pharmaceutical Technology
DECEMBER 3, 2024
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster the neuro-rare disease sector.
Fierce Pharma
DECEMBER 3, 2024
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Pharmaceutical Technology
DECEMBER 3, 2024
J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.
Bio Pharma Dive
DECEMBER 3, 2024
A change in ownership and what it means for our readers.
Pharmaceutical Technology
DECEMBER 3, 2024
Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.
Pharma Times
DECEMBER 3, 2024
Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence (NICE) and is now available through the NHS.
Pharmaceutical Technology
DECEMBER 3, 2024
Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
DECEMBER 3, 2024
The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements
Fierce Pharma
DECEMBER 3, 2024
Following a pair of similar deals in January and June, Coherus BioSciences has netted itself a hefty chunk of change for the last biosimilar in its portfolio, in turn freeing up the company to go a | Coherus has agreed to sell its Neulasta biosimilar Udenyca to Intas Pharmaceuticals for up to $558.4 million. The company plans to use the proceeds from the sale to pay off debt and fuel development opportunities for its branded cancer med Loqtorzi.
pharmaphorum
DECEMBER 3, 2024
Tune in to the podcast interview with Dr Sharmeen Roy to learn more about precision dosing and how DoseMe is providing effective and safe treatment for all through personalised dosing solutions.
XTalks
DECEMBER 3, 2024
Novocure, a global leader in oncology innovation, has long been at the forefront of advancing tumor treating fields (TTFields) therapy. This technology, already approved by the US Food and Drug Administration (FDA) for glioblastoma and mesothelioma , and most recently for metastatic non-small cell lung cancer (NSCLC), harnesses electric fields to disrupt cancer cell division.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Intouch Solutions
DECEMBER 3, 2024
EVERSANA INTOUCH recently hosted an insightful panel at the 2024 ProcureCon Marketing conference in Los Angeles. The panel, titled “The Balancing Act: Sourcing & Pricing Meet Innovation in Life Sciences,” brought together industry leaders to discuss the intersection of cost efficiency and innovation in the dynamic field of life sciences.
XTalks
DECEMBER 3, 2024
The diabetes medication landscape continues to evolve, driven by advancements in drug development, increasing prevalence of the condition and a growing demand for innovative therapies. Diabetes affects millions worldwide, and the pharmaceutical market is responding with treatments that not only improve glycemic control but also address cardiovascular and kidney-related complications, offering holistic management for patients.
pharmaphorum
DECEMBER 3, 2024
Get to know Jackie Marchington, an expert in IPG Health Medical Communications, through this exclusive interview. Learn about her insights, experiences, and perspectives on the industry.
Fierce Pharma
DECEMBER 3, 2024
On the heels of similar deals in the U.S. and the EU, the U.K. is filling up its coffers with doses of bird flu immunizations from Australia’s CSL Seqirus. | On the heels of similar deals in the U.S. and the European Union, the United Kingdom is filling up its coffers with doses of bird flu immunizations from Australia’s CSL Seqirus. To prepare for a potential future pandemic, the U.K. has inked an accord with CSL Seqirus to acquire more than 5 million doses of the company’s H5 influenza shot.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
DECEMBER 3, 2024
Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position
Pharmaceutical Commerce
DECEMBER 3, 2024
The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.
pharmaphorum
DECEMBER 3, 2024
Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy
Drug Patent Watch
DECEMBER 3, 2024
In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
pharmaphorum
DECEMBER 3, 2024
Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.
Drug Patent Watch
DECEMBER 3, 2024
The process of obtaining a patent for a drug invention can be complex and time-consuming. Despite the best efforts of inventors and patent attorneys, many drug patent applications are rejected by patent offices. Understanding the common reasons for these rejections is crucial for overcoming them and securing patent protection for innovative pharmaceuticals.
pharmaphorum
DECEMBER 3, 2024
Integrating Expertise from Software Development, Quality Assurance, Regulatory Affairs, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines, AI & ML Enabled Software, Cybersecurity, & Agile Methodologies
Drug Channels
DECEMBER 3, 2024
It’s time to pay attention to the money behind the 340B curtain. Minnesota just released the industry‘s first ever mandated financial report on the 340B Drug Pricing Program. Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more. There are important limitations to these data.
Expert insights. Personalized for you.
147 
Let's personalize your content